Compare JF & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JF | FEMY |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | China | United States |
| Employees | 30 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1M | 21.9M |
| IPO Year | N/A | 2021 |
| Metric | JF | FEMY |
|---|---|---|
| Price | $0.96 | $3.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 9.3K | ★ 48.8K |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | N/A | $105.16 |
| Revenue Next Year | N/A | $200.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $0.89 | $0.29 |
| 52 Week High | $1.19 | $6.29 |
| Indicator | JF | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 60.93 |
| Support Level | $0.91 | $0.47 |
| Resistance Level | $1.02 | $6.29 |
| Average True Range (ATR) | 0.06 | 0.41 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 6.74 | 35.94 |
J and Friends Holdings Ltd providing merchant digitalization and commerce-enablement solutions to small and medium enterprises (SME). Its solutions feature critical functionality that SMEs need to engage with consumers, manage their operations, accept payments, and grow their business. Such solutions empower single- and multi-location retailers, restaurants, and other SMEs to compete successfully in an omni-channel market environment by engaging with consumers across online, mobile, and physical channels. The group conducts all of its current operations in Australia and generates revenues from continuing operations are derived from within Australia.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.